Short Interest in OpGen, Inc. (NASDAQ:OPGN) Increases By 24.3%
OpGen, Inc. (NASDAQ:OPGN) was the recipient of a large increase in short interest during the month of July. As of July 31st, there was short interest totalling 2,692,022 shares, an increase of 24.3% from the July 14th total of 2,165,093 shares. Based on an average trading volume of 4,261,875 shares, the days-to-cover ratio is presently 0.6 days. Currently, 8.7% of the company’s shares are sold short.
Several brokerages have recently weighed in on OPGN. HC Wainwright set a $1.00 price target on shares of OpGen and gave the company a “buy” rating in a research report on Wednesday. Zacks Investment Research raised shares of OpGen from a “sell” rating to a “hold” rating in a research report on Wednesday, June 28th. Finally, Dawson James reaffirmed a “buy” rating on shares of OpGen in a research report on Monday, June 19th.
In other news, CFO Timothy C. Dec purchased 65,000 shares of the stock in a transaction dated Tuesday, July 18th. The shares were purchased at an average price of $0.40 per share, with a total value of $26,000.00. Following the transaction, the chief financial officer now owns 118,966 shares in the company, valued at approximately $47,586.40. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Chairman Jven Capital, Llc purchased 1,875,000 shares of the stock in a transaction dated Tuesday, July 18th. The shares were purchased at an average cost of $0.40 per share, for a total transaction of $750,000.00. The disclosure for this purchase can be found here. Insiders own 53.27% of the company’s stock.
An institutional investor recently raised its position in OpGen stock. Vanguard Group Inc. increased its position in shares of OpGen, Inc. (NASDAQ:OPGN) by 1.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 342,860 shares of the medical research company’s stock after buying an additional 5,500 shares during the period. Vanguard Group Inc. owned about 1.25% of OpGen worth $219,000 at the end of the most recent quarter. 9.25% of the stock is owned by institutional investors and hedge funds.
OpGen (OPGN) opened at 0.2722 on Friday. OpGen has a 52-week low of $0.26 and a 52-week high of $3.10. The firm’s market cap is $14.03 million. The firm has a 50-day moving average of $0.43 and a 200-day moving average of $0.83.
OpGen Company Profile
OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.
Receive News & Ratings for OpGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.